{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:26:14Z","timestamp":1788492374830,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Multiple sclerosis (MS) results in physical and cognitive impairments that negatively affect health-related quality of life (HRQoL). It is unknown to what extent the impact of MS-related impairments on HRQoL are reflected in the association of Expanded Disability Status Scale (EDSS) Functional Systems (FS) scores and EQ-5D-5L index values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This cross-sectional, single-center cohort study recruited people with MS (pwMS) attending an outpatient clinic at a German university hospital. Impairment was assessed via FS scores during routine visits. HRQoL was measured with EQ-5D-5L index values. The association of each FS score with EQ-5D-5L index values and the additive effect of all FS on EQ-5D-5L index values was modeled with multivariate linear regression (MLR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Analyzing 115 participants, unadjusted MLR of single FS revealed that brainstem, pyramidal, cerebellar, sensory, and cerebral\/cognitive dysfunctions were significantly associated with lower HRQoL. In MLR of all FS adjusted for covariates, a one standard deviation decrease in cognitive function was significantly associated with a 6% reduction in HRQoL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Dysfunctions in FS contribute to a decrease in HRQoL. Cognitive dysfunction was identified to maintain negative association with HRQoL after adjustment for covariates, and routinely assessed FS scores appeared useful indicators to identify pwMS who may benefit from comprehensive cognitive evaluations. This study adds to the growing body of evidence emphasizing the crucial role of cognitive function in HRQoL of pwMS and highlights the need for effective screening and therapeutic strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11136-025-03928-9","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:07:30Z","timestamp":1741259250000},"page":"1773-1781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of impairment on health-related quality of life in people with multiple sclerosis: association of functional systems and EQ-5D-5L index values in a cross-sectional study"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3611-0124","authenticated-orcid":false,"given":"Richard","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Starke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Bednarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8604-8408","authenticated-orcid":false,"given":"Florian","family":"Then Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"14","key":"3928_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., & Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 26(14), 1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Multiple Sclerosis Journal"},{"issue":"11","key":"3928_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444\u20131444. https:\/\/doi.org\/10.1212\/WNL.33.11.1444","journal-title":"Neurology"},{"issue":"6","key":"3928_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40263-018-0530-8","volume":"32","author":"BMJ Uitdehaag","year":"2018","unstructured":"Uitdehaag, B. M. J. (2018). Disability outcome measures in phase III clinical trials in multiple sclerosis. Cns Drugs, 32(6), 543\u2013558. https:\/\/doi.org\/10.1007\/s40263-018-0530-8","journal-title":"Cns Drugs"},{"key":"3928_CR4","unstructured":"Fayers, P. M., & Machin, D. (2013). Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. Wiley."},{"issue":"9","key":"3928_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00019053-200826090-00007","volume":"26","author":"J Brazier","year":"2008","unstructured":"Brazier, J. (2008). Valuing Health states for Use in cost-effectiveness analysis. Pharmacoeconomics, 26(9), 769\u2013779. https:\/\/doi.org\/10.2165\/00019053-200826090-00007","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"3928_CR6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Quality of Life Research"},{"issue":"8","key":"3928_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40273-014-0167-5","volume":"32","author":"A Kuspinar","year":"2014","unstructured":"Kuspinar, A., & Mayo, N. E. (2014). A review of the Psychometric properties of Generic Utility measures in multiple sclerosis. Pharmacoeconomics, 32(8), 759\u2013773. https:\/\/doi.org\/10.1007\/s40273-014-0167-5","journal-title":"Pharmacoeconomics"},{"key":"3928_CR8","doi-asserted-by":"publisher","first-page":"675523","DOI":"10.3389\/fpubh.2021.675523","volume":"9","author":"T Zhou","year":"2021","unstructured":"Zhou, T., Guan, H., Wang, L., Zhang, Y., Rui, M., & Ma, A. (2021). Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: A systematic review. Frontiers in Public Health, 9, 675523. https:\/\/doi.org\/10.3389\/fpubh.2021.675523","journal-title":"Frontiers in Public Health"},{"issue":"8","key":"3928_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt, G., Thompson, A., Berg, J., Gannedahl, M., Eriksson, J., & the MSCOI Study Group, & the European Multiple Sclerosis Platform. (2017). New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis Journal, 23(8), 1123\u20131136. https:\/\/doi.org\/10.1177\/1352458517694432","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"3928_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF02260859","volume":"4","author":"BG Vickrey","year":"1995","unstructured":"Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W., & Ellison, G. W. (1995). A health-related quality of life measure for multiple sclerosis. Quality of Life Research, 4(3), 187\u2013206. https:\/\/doi.org\/10.1007\/BF02260859","journal-title":"Quality of Life Research"},{"issue":"5","key":"3928_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","volume":"124","author":"J Hobart","year":"2001","unstructured":"Hobart, J. (2001). The multiple sclerosis impact scale (MSIS-29): A new patient-based outcome measure. Brain, 124(5), 962\u2013973. https:\/\/doi.org\/10.1093\/brain\/124.5.962","journal-title":"Brain"},{"issue":"8","key":"3928_CR12","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin, M., Slaap, B., Herdman, M., Van Reenen, M., Kennedy-Martin, T., Greiner, W., & Boye, K. S. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European Journal of Health Economics, 21(8), 1245\u20131257. https:\/\/doi.org\/10.1007\/s10198-020-01195-8","journal-title":"The European Journal of Health Economics"},{"key":"3928_CR13","doi-asserted-by":"publisher","first-page":"105139","DOI":"10.1016\/j.msard.2023.105139","volume":"81","author":"A Abdelhak","year":"2024","unstructured":"Abdelhak, A., Antweiler, K., Kowarik, M. C., Senel, M., Havla, J., Zettl, U. K., & Tumani, H. (2024). Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 81, 105139. https:\/\/doi.org\/10.1016\/j.msard.2023.105139","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"3928_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13690-021-00561-z","volume":"79","author":"LA Visser","year":"2021","unstructured":"Visser, L. A., Louapre, C., Uyl-de Groot, C. A., & Redekop, W. K. (2021). Health-related quality of life of multiple sclerosis patients: A European multi-country study. Archives of Public Health\u2009=\u2009Archives Belges De Sante Publique, 79(1), 39. https:\/\/doi.org\/10.1186\/s13690-021-00561-z","journal-title":"Archives of Public Health\u2009=\u2009Archives Belges De Sante Publique"},{"issue":"1","key":"3928_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1477-7525-8-55","volume":"8","author":"S Twork","year":"2010","unstructured":"Twork, S., Wiesmeth, S., Spindler, M., Wirtz, M., Schipper, S., P\u00f6hlau, D., & Kugler, J. (2010). Disability status and quality of life in multiple sclerosis: Non-linearity of the expanded disability status scale (EDSS). Health and Quality of Life Outcomes, 8(1), 55. https:\/\/doi.org\/10.1186\/1477-7525-8-55","journal-title":"Health and Quality of Life Outcomes"},{"issue":"11","key":"3928_CR16","doi-asserted-by":"publisher","first-page":"e041249","DOI":"10.1136\/bmjopen-2020-041249","volume":"10","author":"I Gil-Gonz\u00e1lez","year":"2020","unstructured":"Gil-Gonz\u00e1lez, I., Mart\u00edn-Rodr\u00edguez, A., Conrad, R., & P\u00e9rez-San-Gregorio, M. \u00c1. (2020). Quality of life in adults with multiple sclerosis: A systematic review. British Medical Journal Open, 10(11), e041249. https:\/\/doi.org\/10.1136\/bmjopen-2020-041249","journal-title":"British Medical Journal Open"},{"issue":"8","key":"3928_CR17","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1177\/1352458520958369","volume":"27","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Taylor, B. V., Simpson, S., Blizzard, L., Campbell, J. A., Palmer, A. J., & Van Der Mei, I. (2021). Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype. Multiple Sclerosis Journal, 27(8), 1262\u20131275. https:\/\/doi.org\/10.1177\/1352458520958369","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"3928_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s10198-013-0537-5","volume":"15","author":"UK Zettl","year":"2014","unstructured":"Zettl, U. K., Henze, T., Essner, U., & Flachenecker, P. (2014). Burden of disease in multiple sclerosis patients with spasticity in Germany: Mobility improvement study (move I). The European Journal of Health Economics, 15(9), 953\u2013966. https:\/\/doi.org\/10.1007\/s10198-013-0537-5","journal-title":"The European Journal of Health Economics"},{"issue":"7","key":"3928_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/ene.13010","volume":"23","author":"C Zecca","year":"2016","unstructured":"Zecca, C., Riccitelli, G. C., Disanto, G., Singh, A., Digesu, G. A., Panicari, L., & Gobbi, C. (2016). Urinary incontinence in multiple sclerosis: Prevalence, severity and impact on patients\u2019 quality of life. European Journal of Neurology, 23(7), 1228\u20131234. https:\/\/doi.org\/10.1111\/ene.13010","journal-title":"European Journal of Neurology"},{"issue":"2","key":"3928_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., & Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"The Lancet Neurology"},{"issue":"12","key":"3928_CR21","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/s11136-023-03486-y","volume":"32","author":"H Ahmad","year":"2023","unstructured":"Ahmad, H., Campbell, J. A., Van Der Mei, I., Taylor, B. V., Xia, Q., Zhao, T., & Palmer, A. J. (2023). Estimating the disutility of relapse in relapsing\u2013remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: Implications for health economic evaluation models. Quality of Life Research, 32(12), 3373\u20133387. https:\/\/doi.org\/10.1007\/s11136-023-03486-y","journal-title":"Quality of Life Research"},{"issue":"7624","key":"3928_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"EV Elm","year":"2007","unstructured":"Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., G\u00f8tzsche, P. C., & Vandenbroucke, J. P. (2007). Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Bmj, 335(7624), 806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD","journal-title":"Bmj"},{"issue":"6","key":"3928_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig, K., Schulenburg, G. V. D., J.-M., & Greiner, W. (2018). German value set for the EQ-5D-5L. Pharmacoeconomics, 36(6), 663\u2013674. https:\/\/doi.org\/10.1007\/s40273-018-0615-8","journal-title":"Pharmacoeconomics"},{"key":"3928_CR24","unstructured":"edmus_fs.pdf (n.d.). Retrieved from https:\/\/www.edmus.org\/en\/dl\/scales\/edmus_fs.pdf"},{"issue":"12","key":"3928_CR25","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1177\/1352458518795416","volume":"25","author":"AG Skjerb\u00e6k","year":"2019","unstructured":"Skjerb\u00e6k, A. G., Boesen, F., Petersen, T., Rasmussen, P. V., Stenager, E., N\u00f8rgaard, M., & Dalgas, U. (2019). Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? Multiple Sclerosis Journal, 25(12), 1653\u20131660. https:\/\/doi.org\/10.1177\/1352458518795416. The Danish MS hospitals rehabilitation study.","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"3928_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/oxfordjournals.aje.a114532","volume":"125","author":"SD Walter","year":"1987","unstructured":"Walter, S. D., Feinstein, A. R., & Wells, C. K. (1987). CODING ORDINAL INDEPENDENT VARIABLES IN MULTIPLE REGRESSION ANALYSES. American Journal of Epidemiology, 125(2), 319\u2013323. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114532","journal-title":"American Journal of Epidemiology"},{"key":"3928_CR27","unstructured":"R Core Team (2022). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Retrieved from https:\/\/www.R-project.org\/"},{"key":"3928_CR28","unstructured":"RStudio Team (2022). RStudio: Integrated Development Environment for R. Boston, MA: RStudio, PBC. Retrieved from http:\/\/www.rstudio.com\/"},{"issue":"7","key":"3928_CR29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jval.2020.03.003","volume":"23","author":"EB Henry","year":"2020","unstructured":"Henry, E. B., Barry, L. E., Hobbins, A. P., McClure, N. S., & O\u2019Neill, C. (2020). Estimation of an instrument-defined minimally important difference in EQ-5D-5L Index scores based on Scoring algorithms Derived using the EQ-VT version 2 valuation protocols. Value in Health, 23(7), 936\u2013944. https:\/\/doi.org\/10.1016\/j.jval.2020.03.003","journal-title":"Value in Health"},{"issue":"1","key":"3928_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1352458519868990","volume":"26","author":"A Fambiatos","year":"2020","unstructured":"Fambiatos, A., Jokubaitis, V., Horakova, D., Kubala Havrdova, E., Trojano, M., Prat, A., & Kalincik, T. (2020). Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 26(1), 79\u201390. https:\/\/doi.org\/10.1177\/1352458519868990","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"3928_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and treatment of multiple sclerosis: A review. Journal of the American Medical Association, 325(8), 765\u2013779. https:\/\/doi.org\/10.1001\/jama.2020.26858","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"3928_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12955-021-01719-7","volume":"19","author":"O Marten","year":"2021","unstructured":"Marten, O., & Greiner, W. (2021). EQ-5D-5L reference values for the German general elderly population. Health and Quality of Life Outcomes, 19(1), 76. https:\/\/doi.org\/10.1186\/s12955-021-01719-7","journal-title":"Health and Quality of Life Outcomes"},{"key":"3928_CR33","doi-asserted-by":"publisher","unstructured":"Islamoska, S., Forman, C. R., Panicker, J. N., Flachenecker, P., Ph\u00e9, V., Brichetto,G.,\u2026 Barken, K. B. (2024). The impact of bladder problems on well-being in multiple sclerosis \u2013 A cross-sectional study. Multiple Sclerosis and Related Disorders, 87, 105661. https:\/\/doi.org\/10.1016\/j.msard.2024.105661","DOI":"10.1016\/j.msard.2024.105661"},{"issue":"9","key":"3928_CR34","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1177\/1352458512474860","volume":"19","author":"E Fogarty","year":"2013","unstructured":"Fogarty, E., Walsh, C., Adams, R., McGuigan, C., Barry, M., & Tubridy, N. (2013). Relating health-related quality of life to disability progression in multiple sclerosis, using the 5-level EQ-5D. Multiple Sclerosis Journal, 19(9), 1190\u20131196. https:\/\/doi.org\/10.1177\/1352458512474860","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"3928_CR35","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1212\/WNL.15.7.654","volume":"15","author":"JF Kurtzke","year":"1965","unstructured":"Kurtzke, J. F. (1965). Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology, 15(7), 654\u2013654. https:\/\/doi.org\/10.1212\/WNL.15.7.654","journal-title":"Neurology"},{"key":"3928_CR36","doi-asserted-by":"publisher","first-page":"101895","DOI":"10.1016\/j.msard.2019.101895","volume":"39","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Taylor, B. V., Simpson, S., Blizzard, L., Palmer, A. J., & Van Der Mei, I. (2020). Validation of 0\u201310 MS symptom scores in the Australian multiple sclerosis longitudinal study. Multiple Sclerosis and Related Disorders, 39, 101895. https:\/\/doi.org\/10.1016\/j.msard.2019.101895","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"6","key":"3928_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41582-020-0355-1","volume":"16","author":"J DeLuca","year":"2020","unstructured":"DeLuca, J., Chiaravalloti, N. D., & Sandroff, B. M. (2020). Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nature Reviews Neurology, 16(6), 319\u2013332. https:\/\/doi.org\/10.1038\/s41582-020-0355-1","journal-title":"Nature Reviews Neurology"},{"issue":"1\u20132","key":"3928_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jns.2014.10.021","volume":"347","author":"CE Schwartz","year":"2014","unstructured":"Schwartz, C. E., Ayandeh, A., & Motl, R. W. (2014). Investigating the minimal important difference in ambulation in multiple sclerosis: A disconnect between performance-based and patient-reported outcomes? Journal of the Neurological Sciences, 347(1\u20132), 268\u2013274. https:\/\/doi.org\/10.1016\/j.jns.2014.10.021","journal-title":"Journal of the Neurological Sciences"},{"issue":"13","key":"3928_CR39","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1177\/1352458518803785","volume":"24","author":"R Kalb","year":"2018","unstructured":"Kalb, R., Beier, M., Benedict, R. H., Charvet, L., Costello, K., Feinstein, A., & DeLuca, J. (2018). Recommendations for cognitive screening and management in multiple sclerosis care. Multiple Sclerosis Journal, 24(13), 1665\u20131680. https:\/\/doi.org\/10.1177\/1352458518803785","journal-title":"Multiple Sclerosis Journal"},{"issue":"6","key":"3928_CR40","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458511431076","volume":"18","author":"D Langdon","year":"2012","unstructured":"Langdon, D., Amato, M., Boringa, J., Brochet, B., Foley, F., Fredrikson, S., & Benedict, R. (2012). Recommendations for a brief International Cognitive Assessment for multiple sclerosis (BICAMS). Multiple Sclerosis Journal, 18(6), 891\u2013898. https:\/\/doi.org\/10.1177\/1352458511431076","journal-title":"Multiple Sclerosis Journal"},{"key":"3928_CR41","doi-asserted-by":"publisher","unstructured":"Benedict, R. H. B., Cookfair, D., Gavett, R., Gunther, M., Munschauer, F., Garg, N., & Weinstock-Guttman, B. (2006). Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society, 12(04). https:\/\/doi.org\/10.1017\/S1355617706060723","DOI":"10.1017\/S1355617706060723"},{"issue":"4","key":"3928_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S., Phillips, N. A., B\u00e9dirian, V., Charbonneau, S., Whitehead, V., Collin, I., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief Screening Tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x","journal-title":"Journal of the American Geriatrics Society"},{"issue":"3","key":"3928_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1017\/S0317167100014384","volume":"40","author":"E Dagenais","year":"2013","unstructured":"Dagenais, E., Rouleau, I., Demers, M., Jobin, C., Roger, \u00c9., Chamelian, L., & Duquette, P. (2013). Value of the MoCA Test as a screening instrument in multiple sclerosis. Canadian Journal of Neurological Sciences \/ Journal Canadien Des Sciences Neurologiques, 40(3), 410\u2013415. https:\/\/doi.org\/10.1017\/S0317167100014384","journal-title":"Canadian Journal of Neurological Sciences \/ Journal Canadien Des Sciences Neurologiques"},{"key":"3928_CR44","doi-asserted-by":"publisher","unstructured":"Charvet, L. E. (2015). The Montreal Cognitive Assessment (MoCA) in multiple sclerosis: Relation to clinical features. Journal of Multiple Sclerosis, 02(02). https:\/\/doi.org\/10.4172\/2376-0389.1000135","DOI":"10.4172\/2376-0389.1000135"},{"issue":"7","key":"3928_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1055\/s-2004-831083","volume":"30","author":"P Calabrese","year":"2004","unstructured":"Calabrese, P., Kalbe, E., & Kessler, J. (2004). Ein neuropsychologisches Screening Zur Erfassung Kognitiver St\u00f6rungen bei MS-Patienten - das multiple sklerose Inventarium Cognition (MUSIC). Psychoneuro, 30(7), 384\u2013388. https:\/\/doi.org\/10.1055\/s-2004-831083","journal-title":"Psychoneuro"},{"issue":"6","key":"3928_CR46","doi-asserted-by":"publisher","first-page":"e3009","DOI":"10.1002\/brb3.3009","volume":"13","author":"C Ezegbe","year":"2023","unstructured":"Ezegbe, C., Zarghami, A., Van Der Mei, I., Alty, J., Honan, C., & Taylor, B. (2023). Instruments measuring change in cognitive function in multiple sclerosis: A systematic review. Brain and Behavior, 13(6), e3009. https:\/\/doi.org\/10.1002\/brb3.3009","journal-title":"Brain and Behavior"},{"issue":"2","key":"3928_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0269215517722583","volume":"32","author":"JR Mhizha-Murira","year":"2018","unstructured":"Mhizha-Murira, J. R., Drummond, A., Klein, O. A., & dasNair, R. (2018). Reporting interventions in trials evaluating cognitive rehabilitation in people with multiple sclerosis: A systematic review. Clinical Rehabilitation, 32(2), 243\u2013254. https:\/\/doi.org\/10.1177\/0269215517722583","journal-title":"Clinical Rehabilitation"},{"issue":"6","key":"3928_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1017\/cjn.2022.334","volume":"50","author":"SA Morrow","year":"2023","unstructured":"Morrow, S. A., Baldwin, C., & Alkabie, S. (2023). Importance of identifying cognitive impairment in multiple sclerosis. Canadian Journal of Neurological Sciences \/ Journal Canadien Des Sciences Neurologiques, 50(6), 813\u2013819. https:\/\/doi.org\/10.1017\/cjn.2022.334","journal-title":"Canadian Journal of Neurological Sciences \/ Journal Canadien Des Sciences Neurologiques"},{"issue":"6","key":"3928_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000322140","volume":"64","author":"H Brissart","year":"2010","unstructured":"Brissart, H., Sauv\u00e9e, M., Latarche, C., Dillier, C., & Debouverie, M. (2010). Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosis. European Neurology, 64(6), 345\u2013350. https:\/\/doi.org\/10.1159\/000322140","journal-title":"European Neurology"},{"key":"3928_CR50","doi-asserted-by":"publisher","unstructured":"Frau, J., Mulasso, A., Coghe, G., Melis, M., Beratto, L., Cuomo, S.,\u2026 Cocco, E.(2023). Multidimensional frailty and its association with quality of life and disability:A cross-sectional study in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 79, 105036. https:\/\/doi.org\/10.1016\/j.msard.2023.105036.","DOI":"10.1016\/j.msard.2023.105036"},{"key":"3928_CR51","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.msard.2020.102724","volume":"49","author":"S Lynch","year":"2021","unstructured":"Lynch, S., Baker, S., Nashatizadeh, M., Thuringer, A., Thelen, J., & Bruce, J. (2021). Disability measurement in multiple sclerosis patients 55 years and older: What is the expanded disability status scale really telling clinicians? Multiple Sclerosis and Related Disorders, 49, 102724. https:\/\/doi.org\/10.1016\/j.msard.2020.102724","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"3928_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.healthpol.2018.12.003","volume":"123","author":"O Efthymiadou","year":"2019","unstructured":"Efthymiadou, O., Mossman, J., & Kanavos, P. (2019). Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. Health Policy, 123(2), 159\u2013165. https:\/\/doi.org\/10.1016\/j.healthpol.2018.12.003","journal-title":"Health Policy"},{"issue":"2","key":"3928_CR53","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11136-022-03214-y","volume":"32","author":"JA Campbell","year":"2023","unstructured":"Campbell, J. A., Ahmad, H., Chen, G., Van Der Mei, I., Taylor, B. V., Claflin, S., & Palmer, A. J. (2023). Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia. Quality of Life Research, 32(2), 553\u2013568. https:\/\/doi.org\/10.1007\/s11136-022-03214-y","journal-title":"Quality of Life Research"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-025-03928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-025-03928-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-025-03928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:01:05Z","timestamp":1748433665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-025-03928-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3928"],"URL":"https:\/\/doi.org\/10.1007\/s11136-025-03928-9","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"13 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with guidelines of the Declaration of Helsinki and was approved by the institutional review board of the Medical Faculty of Leipzig University, Leipzig, Germany (reference number 063\/23-ek). Written informed consent was obtained from all participants. The study was registered in the German Clinical Trial Register (reference number DRKS00031556).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"RS has received travel grants from Alexion Pharma Germany GmbH, Hanns Martin Schleyer Foundation, Congress of the European Committee for Treatment and Research in Multiple Sclerosis, and the German Neurological Society. AS has nothing to declare. NB has nothing to declare. FTB has received, over his academic career, research support and travel grants to attend scientific meetings, through his institution, from the German Science Fund (DFG), German Federal Ministry of Education and Science (BMBF), Bayer-Schering, Diamed, Fresenius, Merck, Novartis, Pfizer, Roche, Sanofi and Teva; speaker fees and compensation for advisory boards from Actelion, Alexion, Bayer, Biogen, CSL Behring, Fresenius, Horizon, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda and Teva; none were related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}